Virbac launches new canine epilepsy therapy EpiRepress

Virbac has announced the launch of a user-friendly new canine epilepsy treatment called EpiRepress.

The therapy uses the active ingredient phenobarbital – the only ingredient licensed to treat both idiopathic and structural epilepsy – and is offered at the conventional 60 mg tablet strength, which can be split into two or four to enable tailored dosing.

It is the first epilepsy treatment to be offered in easy-to-dispense boxes of 30 tablets, removing the need for vets to count out tablets from larger pots. The smaller box size also makes the product more affordable for pet owners.

To accompany the launch of EpiRepress, Virbac is launching several complementary resources, including an epilepsy diary filled with useful questions and tips, as well as a handy folder in which to keep the diary and accompanying materials.

A diagnostic and treatment poster has also been made available for vet practices to provide information about the product.

Sarah Dixon, a product manager at Virbac, said: "Phenobarbital is the mainstay treatment for canine epilepsy and, in developing our product, we wanted to offer practices and owners an easier, more accurate and more cost-effective solution."

With over 20 years of experience within the animal health market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current animal health roles we have available, you can search for the latest job roles, register your details, or contact the team today.